Top Page
Shield Therapeutics
(LSE:STX)
Shield Therapeutics (STX) vs. iShares MSCI United Kingdom ETF (EWC)
Shield Therapeutics Business Overview & Revenue Model
Shield Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.07M | 25.18M | 13.09M | 5.50M | 1.52M | 10.39M |
| Gross Profit | 14.32M | 10.57M | 4.03M | 2.00M | 539.00K | 9.03M |
| EBITDA | -9.93M | -16.58M | -30.29M | -46.07M | -17.69M | 820.00K |
| Net Income | -16.42M | -21.27M | -33.29M | -40.44M | -19.34M | -2.63M |
Balance Sheet | ||||||
| Total Assets | 62.10M | 45.90M | 48.80M | 22.07M | 44.41M | 32.53M |
| Cash, Cash Equivalents and Short-Term Investments | 10.81M | 5.61M | 13.95M | 2.82M | 12.12M | 2.94M |
| Total Debt | 27.05M | 21.06M | 20.41M | 6.10M | 156.00K | 28.00K |
| Total Liabilities | 76.96M | 46.95M | 26.49M | 16.65M | 3.38M | 2.25M |
| Stockholders Equity | -14.86M | -1.05M | 11.79M | 5.43M | 40.69M | 30.28M |
Cash Flow | ||||||
| Free Cash Flow | -8.15M | -7.03M | -40.07M | -20.14M | -18.80M | -1.42M |
| Operating Cash Flow | -8.15M | -7.01M | -37.13M | -18.25M | -16.74M | -1.40M |
| Investing Cash Flow | -1.30M | -1.89M | -2.43M | -1.70M | -2.05M | -20.00K |
| Financing Cash Flow | 11.83M | 4.21M | 49.66M | 7.71M | 27.58M | -47.00K |
Shield Therapeutics Technical Analysis
Shield Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £3.33B | 11.67 | 15.66% | 4.17% | 3.73% | 27.13% | |
67 Neutral | £164.33M | -6.71 | 2.83% | 2.18% | 8.74% | -166.50% | |
63 Neutral | £119.45M | -5.91 | -396.71% | ― | 93.48% | 51.18% | |
57 Neutral | £706.27M | -13.45 | ― | ― | -0.28% | 22.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shield Therapeutics Corporate Events
Shield Therapeutics has amended its senior secured debt financing, enhancing its financial position by increasing available funds to $50 million, with $15 million earmarked for future mergers and acquisitions. The revised terms, achieved through collaboration with SWK Holdings and Runway Growth Finance, lower debt costs and extend the interest-only period, providing Shield with greater flexibility to pursue growth opportunities and strengthen its market position in the pharmaceutical industry.
Shield Therapeutics announced the initiation of a Phase II clinical trial in Japan for ACCRUFeR® (ferric maltol) as a treatment for Pulmonary Arterial Hypertension (PAH). This trial, conducted by its partner MEDLEAP Pharma, aims to support a Phase III trial and potential regulatory submissions by 2028. The development is significant as it addresses the challenges of long-term iron supplementation in PAH patients, potentially positioning ACCRUFeR® as a core treatment in this field.
Shield Therapeutics announced the presentation of pediatric pharmacokinetic results for ferric maltol at the upcoming American Society of Hematology Conference. The study confirmed the suitability of ferric maltol for iron replacement in children, supporting its potential expansion to younger populations and highlighting its importance in addressing unmet medical needs in pediatric iron deficiency treatment.
Shield Therapeutics has announced that its product, ACCRUFeR®, has received marketing authorization from the Korean Ministry of Food and Drug Safety for treating iron deficiency in adults. This approval, following a successful pharmacokinetic study and new drug application by Korea Pharma, signifies a major advancement in expanding ACCRUFeR®’s availability in South Korea. Shield is set to receive payments and royalties from sales in the region, reinforcing its commitment to global patient access and highlighting the strength of its international partnerships.
Shield Therapeutics reported its strongest quarterly performance to date, with a 15% increase in ACCRUFeR® prescriptions over the previous quarter, achieving net revenues of $13.1 million. The company remains on track to become cash flow positive by the end of 2025, driven by strategic marketing initiatives and strong sales efforts, marking a significant milestone in its operational progress.
Shield Therapeutics announced the grant of share options to its CEO, Anders Lundstrom, as part of the company’s Retention and Performance Share Plan. This move is part of Lundstrom’s annual equity grant, with options granted over 1,547,262 ordinary shares. The grant reflects Shield’s commitment to retaining key leadership as it continues to focus on its market-leading product, ACCRUFeR®, which addresses a significant unmet need in iron deficiency treatment. The company’s strategic positioning in the pharmaceutical industry is reinforced by its global licensing agreements and the growing market opportunity for its flagship product.
Shield Therapeutics has announced that its total issued share capital consists of 1,061,802,812 ordinary shares, each with equal voting rights, as per FCA’s Disclosure and Transparency Rule. The company’s flagship product, ACCRUFeR®, is the first FDA-approved oral iron treatment for iron deficiency, representing a significant market opportunity and addressing unmet medical needs.
Shield Therapeutics announced positive results from its Phase 3 pediatric trial of ferric maltol, presented at the American Association of Pediatrics Conference. The study demonstrated significant improvements in hemoglobin levels and a favorable safety profile, marking an important milestone for expanding ACCRUFeR®’s use in young children. This development could enhance Shield’s market position by addressing a critical unmet need for safe and effective oral iron treatments in pediatric populations.
Shield Therapeutics has successfully raised £1.5 million through a placing of new ordinary shares, driven by unsolicited institutional investor demand, to support the growth of its leading product, ACCRUFeR®, in the U.S. market. This financial move, which involved issuing shares at a premium, aims to strengthen the company’s working capital and broaden its shareholder base, positioning Shield to accelerate sales and achieve positive cash flow by the end of 2025.